Identifying pediatric hypertension in observational data: comparing clinical and claims cohorts in real-world data
American Journal of Epidemiology · 2025
DOI: 10.1093/aje/kwae233 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Casie E Horgan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United States. Hauptthemen laut MEDLINE: Hypertension. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: HHS, FDA HHS, Department of Health and Human Services.
Abstract (Originalsprache)
We conducted retrospective public health surveillance using data from 2006 to 2016 in 7 integrated delivery systems from the US Food and Drug Administration’s Sentinel System. We identified pediatric hypertensive patients by clinical and claims-based definitions and compared demographics, baseline profiles, and follow-up time profiles. Among 3 757 803 pediatric patients aged 3 to 17 years, we identified 781 722 children and 551 246 teens with at least 3 blood pressure measurements over 36 months. Of these, 70 315 children (9%) and 47 928 teens (8.7%) met the clinical definition for hypertension, and 22 465 (2.8%) children and 60 952 (11%) of teens met the clinical definition for elevated, nonhypertensive blood pressure. Of the 3.7 million patients, we identified 3246 children and 7293 teens with any claim for hypertension (claims definition). Evidence of hypertension claims among those meeting our clinical definition was poor; 2.2% and 7.3% of clinically hypertensive children and teens had corresponding claims for hypertension. Baseline profiles for patients with claims-based hypertension suggest greater severity of disease compared with clinical patients. Claims-based patients had higher rates of all-cause mortality during follow-up. Pediatric hypertension in claims-based data sources is under-captured but may serve as a marker for greater disease severity. Investigators should understand coding practices when selecting real-world data sources for pediatric hypertension work.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United States.
- Office of Surveillance and Epidemiology, Center for Drug and Evaluation, U.S. Food and Drug Administration, Silver Spring, MD, United States.
- StatLog Econometrics Inc., Quebec City, QC, Canada.
- Office of Pediatric Therapeutics, Office of the Chief Medical Officer, U.S. Food and Drug Administration, Silver Spring, MD, United States.
ORCID-Profile: Casie E Horgan, Efe Eworuke, Danijela Stojanovic, Jennifer G Lyons, Judith C Maro
Förderung
- HHS
- FDA HHS
- Department of Health and Human Services
- Food and Drug Administration
Zitieren
APA
Horgan, C. E., Burk, J., Eworuke, E., Stojanovic, D., Lyons, J. G., Moyneur, È., McMahon, A., & Maro, J. C. (2025). Identifying pediatric hypertension in observational data: comparing clinical and claims cohorts in real-world data. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwae233
Vancouver
Horgan CE, Burk J, Eworuke E, Stojanovic D, Lyons JG, Moyneur È, et al. Identifying pediatric hypertension in observational data: comparing clinical and claims cohorts in real-world data. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwae233
BibTeX
@article{Horgan2025,
author = {Horgan, Casie E and Burk, Jillian and Eworuke, Efe and Stojanovic, Danijela and Lyons, Jennifer G and Moyneur, Èrick and McMahon, Ann and Maro, Judith C},
title = {Identifying pediatric hypertension in observational data: comparing clinical and claims cohorts in real-world data},
journal = {American Journal of Epidemiology},
year = {2025},
doi = {10.1093/aje/kwae233}
}
EUVIMED